{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJzm65YKDA","lastupdate":"2024-06-04T00:00:00.000Z","update_date":"2024-06-04T00:00:00.000Z","lastModified":"Jan 5, 2025","active":1,"confidence_score":100,"confidence_score_reason":"markets","urlname":"nucleai","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$eOzUd6AY1bx7e3hU7ZOp773EdpuzthMglqf079ifRuRMsJQIhZ976L.png","name":"Nucleai","oneliner":"Spatial Biology Software Platform for Precision Medicine","registrar":"515742096","website":"https://nucleai.ai/","careerspage":"https://nucleai.ai/careers","founded_month":7,"founded_year":2017,"formernames":["nuclai"],"sociallinks":{"twitter":"https://twitter.com/nucleai_ai","youtube":"https://www.youtube.com/channel/UCDs2VIzHSJZ5ehWsG6bqcAw","facebook":"","linkedin":"https://www.linkedin.com/company/25166605","instagram":""},"social":["https://twitter.com/nucleai_ai","https://www.linkedin.com/company/25166605","https://www.youtube.com/channel/UCDs2VIzHSJZ5ehWsG6bqcAw"],"flattenedsociallinks":"https://twitter.com/nucleai_ai|https://www.linkedin.com/company/25166605|https://www.youtube.com/channel/UCDs2VIzHSJZ5ehWsG6bqcAw","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"51-200","employees_exact":76,"patent":1,"raised":60500000,"stage":"B","public_stage":"B","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Nucleai’s technology leverages intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions in a patient’s biopsy, translating them into actionable insights that can accelerate the development of life-saving treatments and diagnostics. \n\nThe company deploys an AI spatial tool for patient selection in a clinical trial, in partnership with a top 10 biopharma company. The platform pioneers AI-driven spatial biomarker analysis, offering a first-of-its-kind multimodal solution. It ingests images from various modalities (H&E, IHC, and multiplex immunofluorescence), conducts advanced spatial analysis, and delivers actionable insights. These insights empower pathologists and researchers with an AI-powered data-rich action plan, paving the way for more informed decisions in the development of next-generation treatments such as bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. \n\nNucleai is working with more than 60 percent of the Top 20 biopharma companies in the world, and has an ecosystem of partners across diagnostics, contract research organizations (CROs), and life sciences tools companies.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"90aa626b-60e4-4155-ab2f-840276bfaad7","city":"Tel Aviv-Yafo","type":null,"address":"Ein Zeitim St 4, Tel Aviv-Yafo, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"GIpqHBWaVWFT3YeOGJE64A0ootaxxOGzc33NNPXKvS8CgIYEJGoLg6","city":"Chicago","address":"1375 W Fulton St, Chicago, IL 60607, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"RAP3JdohTP659nPh7R9ySzCtOofBSNsg6Bk9UNUeLR0MEa57p44JZo","date":"Jun 26, 2024","link":"https://www.geektime.co.il/nucleai-layoffs-2024/?_atscid=7_134353_204082920_2610764_0_Txtetaxjxdshwhus8sp","source":"www.geektime.co.il","visible":1,"analysis":null,"sentiment":null,"analysisId":"TBnZx4RS0FDKUdgF5H8tSjOSkymJts0KXc1b9wsbBEdjBLhK9QqEyb","news_summary":"הסטארטאפ Nucleai מפטר 15% מהעובדים","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"og0zRZQcyRqgQakItJFvUEpINRdnySo8V1BSY4zTBhM00yJtgGbK7q","date":"Jun 24, 2024","link":"https://hitconsultant.net/2024/06/25/proscia-and-nucleai-partner-to-integrate-predictive-biomarker-solutions/","source":"hitconsultant.net","visible":1,"analysis":{"tags":"Partnership, AI, Pathology","company":"Proscia, Nucleai","layoffs":"N/A","summary":"Proscia, a provider of AI-powered pathology solutions, and Nucleai, a spatial AI biomarker company, have announced a strategic partnership. The collaboration aims to integrate Nucleai’s biomarker technology with Proscia’s Concentriq software platform to improve the efficiency and effectiveness of developing new treatments and delivering patient care. Nucleais AI technology analyzes whole slide images, generating spatial maps that predict therapeutic outcomes. Proscia’s Concentriq platform serves as a central hub for all digital pathology data and AI-enabled workflows across the entire diagnostic process.","partners":"Nucleai","customers":"Top 20 biopharmaceutical companies","investors":"N/A","confidence":8,"key_topics":"Artificial Intelligence, Digital Pathology, Precision Medicine, Biomarker Technology, Clinical Trials","date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Partners","acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"53Rb1bP6GV4LnbmIDHf4jZzbhshQlwjzjnoZnh4KQ6ivEVJMW1ptFa","news_summary":"Proscia and Nucleai Partner to Integrate Predictive Biomarker Solutions","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"y7nQ4wEWcGTGXCOfmBt31q70kHF1vgPeFmnuRSsZ8Wi7UlMMvis39N","date":"Apr 8, 2024","link":"https://www.businesswire.com/news/home/20240408865435/en/Nucleai-and-GoPath-Diagnostics-Announce-Strategic-Collaboration-to-Provide-Integrated-AI-powered-Digital-Pathology-Solutions-for-Clinical-Research-and-Diagnostic-Applications","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"49DhD9im9DYaiwiM4U0Wu3E87fcspg6ZisGYQKPY2v44GXLRiBimCg","news_summary":"Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"q69omncnuEGYl1eN9aU3ARmrfk0BIUQ9h8WZPSaJdRNTHO000qmx7x","date":"Apr 3, 2024","link":"https://www.calcalistech.com/ctechnews/article/r11brac1a","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"Investment, AI, Healthcare","company":"Nucleai","layoffs":"Not mentioned","summary":"Nucleai, an AI biomarker company, has secured a $14 million investment led by M Ventures, the corporate venture capital arm of Merck KGaA. The funding will be used to further deploy its AI algorithms for the prospective enrollment of patients in clinical trials. Nucleais technology provides pathologists with the intelligence to anticipate and navigate complex diseases, like cancer. The company has collaborations with over 60% of the top 20 biopharma companies. The funding will also support Nucleais work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics.","partners":"Not mentioned","customers":"Not mentioned","investors":"M Ventures, Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, Grove Ventures","confidence":9,"key_topics":"AI, Machine Learning, Healthcare, Investment, Clinical Trials","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$14 million","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Dl5uUfg2YDtHA7TseGLFyu90e02LSZ8yk3UESBj2RD41XiS7KNhJYA","news_summary":"Spatial AI biomarker startup Nucleai raises $14 million led by Merck's VC arm | CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Ndk0XGkiqTUhzjIDYuSM278bMUZIziluzlA44S2UOoK5r3DjsxdTZV","date":"Sep 8, 2022","link":"https://www.businesswire.com/news/home/20220908005132/en/Lunaphore-and-Nucleai-announce-a-partnership-to-provide-AI-powered-spatial-biology-analysis-to-accelerate-drug-development","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"R61xWQfC596W51BdbqTpKRn0sDZEoK32Iq4fGGjS9qf2HAwEA488OW","news_summary":"Lunaphore and Nucleai announce a partnership to provide AI-powered spatial biology analysis to accelerate drug development","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"3X5CcoOgfHsYk61jHzJKYKaTE9qBn0Mhhf8235mLfDetjrbdcYT75K","date":"Sep 6, 2022","link":"https://www.businesswire.com/news/home/20220906005125/en/Nucleai-Announces-New-Data-Showing-Better-Prediction-of-Response-to-Immune-Checkpoint-Inhibitors-for-NSCLC-Patients","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"YCR9ZH1cAKH7c0qIb4LJ4d7RjXuW07bsgxDr5ny87nlB4uTPROo2SV","news_summary":"Nucleai Announces New Data Showing Better Prediction of Response to Immune Checkpoint Inhibitors for NSCLC Patients","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"VPoOj93YCHe95H4amrsYlylVyaxta94Vxnt1ehkTjAoQrITGLCGXCG","date":"Aug 2, 2022","link":"https://www.businesswire.com/news/home/20220802005702/en/Nucleai-Appoints-New-Head-of-Pathology-to-Support-Expansion-in-Biopharmaceutical-and-Clinical-Markets","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"sVEFipJonjrNDcYH38zHoJ5LdvfCOULfY7UWkdGnwoWVOmU6TVhAvS","news_summary":"Nucleai Appoints New Head of Pathology to Support Expansion in Biopharmaceutical and Clinical Markets","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"eKh5qyLQ6SJcJIUoY0yVHfleooeLWYJplJQIGkUMylm9NTNpE6G7zU","date":"Jul 18, 2022","link":"https://nocamels.com/2022/07/spatial-biology-partners-us-company/","source":"nocamels.com","visible":1,"analysis":{"tags":"partnership, AI-driven discovery","company":"Nucleai","layoffs":null,"summary":"Israeli startup Nucleai has partnered with US-based contract research organization Sirona DX to further the AI-driven discovery of novel spatial biomarkers in solid tumors. Nucleais precision oncology platform combines AI spatial analytics with Sirona Dxs expertise to uncover spatial signatures that predict response to therapy. The partnership aims to support biopharma clinical trials and improve patient care. Nucleai previously raised $33 million in a Series B funding round to expand its spatial biology platform.","partners":"Sirona DX","customers":null,"investors":null,"confidence":9,"key_topics":["Nucleai","Sirona DX","AI-driven discovery","spatial biomarkers","precision oncology"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$33 million","structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vfdoNkfJwoFXDss36xfDf3do0N0LqMPNB5orXRyeniP0hZuyZltgiT","news_summary":"Nucleai Announces a Partnership with Sirona Dx for AI-Driven Discovery of Novel Spatial Biomarkers in Solid Tumors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"D7qnakeHBq5HMalHDv7gwgDLJ5ZHo1gs7bGenhiAPwJWReYNNw0FBx","date":"Jun 2, 2022","link":"https://www.businesswire.com/news/home/20220602005642/en/Nucleai-Announces-Partnership-with-Ultivue-to-Provide-AI-Powered-Spatial-Biology-Analysis-to-Complex-Pathology-Images","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"oKEGrxxpVRBaTtYhC0avPrI5dJFZhsB8qrZEuGCmp6ge3UUNcJmDwx","news_summary":"Nucleai Announces Partnership with Ultivue to Provide AI-Powered Spatial Biology Analysis to Complex Pathology Images","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"3818e0bd-0c9e-4788-8b32-d37cb5582b7b","date":"Mar 22, 2022","link":"https://www.calcalist.co.il/ctechnews/article/rjiw007pg9","source":"www.calcalist.co.il","visible":1,"analysis":{"tags":"spatial biology, oncological treatment","company":"Nucleai","layoffs":null,"summary":"Israeli startup Nucleai has raised $33 million in Series B funding led by Section 32 and Sanofi Ventures. The company has developed technology that allows better prediction of a patients response to specific oncological treatment, improving the chances of developing new cancer drugs. The funding brings Nucleais total investment to $50 million. Nucleais platform is being adopted by pharmaceutical companies worldwide to analyze the rich information available in biopsies and produce scientific discoveries that can change the treatment of cancer.","partners":null,"customers":null,"investors":"Section 32, Sanofi Ventures, Debiopharm, Fosun RZ Capital, Vertex Ventures Israel, Grove Ventures","confidence":8,"key_topics":["Nucleai","Series B funding","Spatial biology","Oncological treatment","Prediction of patients response"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$33 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"n0qjm2kUQSupYNXdBgMJStoCBxxoK0ruRgNNZ6AzuQh2J59DuW0sdT","news_summary":"Nucleai raises $33 million for spatial biology drug development platform  CTech","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9f9904c3-597f-4230-a83b-7a57a582ad8f","date":"Jan 2, 2022","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3926249,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"precision medicine, artificial intelligence, big data, computational biology","company":"Nucleai","layoffs":null,"summary":"Israeli startup Nucleai combines artificial intelligence, big data, and computational biology to develop precision medicine solutions for cancer treatment. The companys software uses computer vision and machine learning algorithms to predict the progress of cancerous tumors and individual patients immune system responses. Nucleai is working with pharmaceutical companies to develop better drugs and recommends cancer patients enroll in clinical trials. The company has raised $15 million in funding from investors including Debiopharm, Vertex Ventures, Grove Ventures, and Fusun RZ Capital. Nucleai plans to expand its operations and open branches in Boston and the Bay Area.","partners":null,"customers":null,"investors":["Debiopharm","Vertex Ventures","Grove Ventures","Fusun RZ Capital"],"confidence":9,"key_topics":["precision oncology","spatial biology","artificial intelligence","pharmaceutical companies","clinical trials"],"date_of_event":"02.01.22","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$15 million","structured_issues":["Partners","Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"eOJIIpkatvFmvzYJpjSLwOqyQEFA2QSeciQ6KC7Ya6TgBJ3Q9Y4EhL","news_summary":"The Israeli startup using spatial biology to provide better cancer treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"304faf03-5291-4c7d-b50c-e32787fa2a6d","date":"Jun 24, 2021","link":"https://www.businesswire.com/news/home/20210624005753/en/Nucleai-and-Merck-KGaA-Darmstadt-Germany-Launch-Translational-Medicine-Collaboration-Utilizing-Nucleai%E2%80%99s-AI-Powered-Biomarker-Platform","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"OhB0rHglr3gAvQnLqD0NLbLpoTvXPoxWKeyjbyQwVVFommWJsmic9E","news_summary":"Nucleai and Merck KGaA Darmstadt, Germany Launch Translational Medicine Collaboration Utilizing Nucleai's AI-Powered Biomarker Platform","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"7167848f-6614-449f-9ac3-0c061db26454","date":"Mar 8, 2021","link":"https://www.jpost.com/health-science/israeli-ai-firm-nucleai-sheba-launch-partnership-for-data-collaboration-661267","source":"www.jpost.com","visible":1,"analysis":{"tags":"strategic data collaboration","company":"Nucleai","layoffs":null,"summary":"Israeli AI firm Nucleai is partnering with Sheba Medical Centers ARC Innovation Center for a strategic data collaboration. Nucleai will gain access to millions of patient records at Sheba Medical Center, including pathology images, clinical data, genomics, and radiomics. The partnership aims to advance the study of technological and AI-based solutions in the discovery of histological biomarkers. Nucleai and Sheba have previously collaborated on identifying biomarkers for non-small-cell lung cancer patients. They have successfully demonstrated the prediction efficiency of tumor microenvironment AI-based analysis for breast cancer. Nucleai plans to leverage Shebas data repository to enhance their AI and machine learning algorithms and develop robust digital pathology platforms.","partners":["Sheba Medical Center"],"customers":null,"investors":null,"confidence":9,"key_topics":["AI-based solutions","histological biomarkers","data collaboration","breast cancer","digital pathology platforms"],"date_of_event":"MARCH 8, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oDKJdvD0EnMJjMZmNenwlXH3b1XZh3k3lQ0aY93xgzmncDkMKRPu5S","news_summary":"https://www.jpost.com/health-science/israeli-ai-firm-nucleai-sheba-launch-partnership-for-data-collaboration-661267","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b61d75c0-84a4-414f-8b8d-9ad41b67d9ba","date":"Jan 14, 2021","link":"https://www.debiopharm.com/digital-health-investment/press-releases/nucleai-and-debiopharm-launch-research-collaboration-utilizing-nucleais-ai-powered-biomarker-platform/","source":"www.debiopharm.com","visible":1,"analysis":{"tags":"biomarker discovery","company":"Nucleai","layoffs":null,"summary":"Nucleai and Debiopharm have entered into a long-term collaboration to leverage Nucleais AI-powered biomarker research & discovery platform for one of Debiopharms clinical stage oncology assets. Nucleais platform analyzes tissue images using computer vision and machine learning to create unique histological biomarkers that can predict patient response. This collaboration could result in better patient selection and improved clinical performance for Debiopharms therapeutic development programs in oncology. The agreement includes an initial installment to Nucleai followed by success-based milestone payments.","partners":"Debiopharm","customers":null,"investors":"Debiopharm","confidence":9,"key_topics":["AI-powered biomarker discovery","long-term collaboration","pathology-based platform","clinical stage oncology assets","artificial intelligence"],"date_of_event":"2021-01-14","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cwiXaOCYDslhqRZ57EOidlPlcasdXiMmoUEUwlnHvRTUzwsQiZmppf","news_summary":"Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai's AI-Powered Biomarker Platform - Debiopharm","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"34fc9933-56d1-45bc-94d2-5a3c05d86f25","date":"Dec 14, 2020","link":"https://www.forbes.com/sites/gilpress/2020/12/14/how-ai-helps-advance-immunotherapy-and-precision-medicine/?sh=5c069df8129a","source":"www.forbes.com","visible":1,"analysis":{"tags":"precision medicine","company":"Nucleai","layoffs":null,"summary":"Tel-Aviv-based startup Nucleai is developing AI software for image analysis and modeling of pathology data to assist in the development of more effective drugs. The company aims to be a leader in precision medicine and uses a multi-disciplinary approach to address the challenge of ineffective predictive biomarkers. Nucleais novel approach to spatial biology helps identify predictive patterns for better selection of candidates in drug trials. The company has raised $13 million, including $8 million in a series A round led by Debiopharm Group. Other investors include Grove Ventures and Vertex Ventures Israel. Nucleai differentiates itself through big data analysis and its go-to-market approach. The article highlights the potential of AI in pathology and the need for a digital transformation in the field.","partners":["Debiopharm Group"],"customers":null,"investors":["Debiopharm Group","Grove Ventures","Vertex Ventures Israel"],"confidence":8,"key_topics":["AI software","predictive biomarkers","spatial biology","big data analysis","digital transformation"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$13 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Yg0W2i3wpnW4dfJ4lBqilTXOGtsVw4T9YMxTYl4fK7tpvbnACjgSAF","news_summary":"How AI Helps Advance Immunotherapy And Precision Medicine","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"67f18e08-c32e-4f5e-b7ea-9e36a433dc05","date":"Oct 14, 2020","link":"https://www.globes.co.il/news/article.aspx?did=1001345526","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Investment, Healthcare, AI","company":"NucleAI","layoffs":"Not mentioned","summary":"Israeli company NucleAI, which uses artificial intelligence to interpret medical imaging for personalised cancer treatment, has raised $8.5m in a funding round led by Swiss pharmaceutical company Debiopharm. The company is working with drug companies and insurers on long-term contracts that are expected to generate millions of dollars in revenue. NucleAI, which employs 30 people, was founded in 2017 by Avi Veidman, Eliron Amir and Lotan Chorev.","partners":"Not mentioned","customers":"Not mentioned","investors":["Debiopharm","Vortex Ventures","Grove Ventures","Nir Kalkstein","Shmuel Zisman"],"confidence":8,"key_topics":["Cancer treatment","AI technology","Investment","Healthcare","Personalized medicine"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$8.5 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kOiG9hpEqmwSZNQ6ivYa1tYee3t8CYSRGCD0MB4DMb0QDb85oC15o3","news_summary":"החברה שמנבאת הצלחת תרופות לסרטן על ידי פענוח הדמיות","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"23716c72-50ec-4ede-b3b8-c3fdd7dfd418","date":"Jul 7, 2020","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3838379,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"cancer detection","company":"Nucleai Ltd.","layoffs":null,"summary":"Tel Aviv-based cancer detection startup Nucleai Ltd. has raised $6.5 million in a series A round led by Debiopharm Group. The funding will be used for research and development and expanding commercial reach. Nucleais software uses computer vision and machine learning to predict tumor progress and patient immune system response for efficient treatment. Nucleai and Debiopharm will collaborate on predictive biomarker discovery and improving clinical trial data. Nucleai was founded in 2017 and employs 30 people. The company plans to raise an additional $2-3 million to complete the funding round.","partners":"Debiopharm Group","customers":null,"investors":"Debiopharm Group","confidence":9,"key_topics":["cancer detection","machine learning","funding","collaboration","biomarker discovery"],"date_of_event":"2020-07-07","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$6.5 million","structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2eKuZtDgTYhS2KvRQzAygrV2GdPQV58MIkGwF42cIvPlEoTXVHXiQZ","news_summary":"AI cancer treatment startup Nucleai raises $6.5 million in series A round","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"be69fb31-ba98-4503-bbe2-4dc73a087286","date":"May 10, 2019","link":"https://www.cioreview.com/news/nucleai-partners-with-protean-biodiagnostics-to-improve-cancer-diagnosis--nid-28698-cid-175.html","source":"www.cioreview.com","visible":1,"analysis":{"tags":"partnership","company":"Nucleai","layoffs":null,"summary":"Nucleai, an AI company, has partnered with Protean BioDiagnostics to enhance cancer diagnostic technology. They will synchronize Nucleais AI-based services with Protean BioDiagnostic laboratories advanced diagnostic tools. The partnership aims to improve diagnostic evaluation and advance personalized oncology technology. Nucleai will benefit from Protean BioDiagnostics expertise in precision medicine, while Protean BioDiagnostics will gain access to Nucleais advanced AI technology. The collaboration holds promise for better diagnostics and reduced biopsy bottleneck.","partners":["Protean BioDiagnostics"],"customers":null,"investors":null,"confidence":9,"key_topics":["AI","cancer diagnostics","precision medicine","biotech","collaboration"],"date_of_event":"Friday, May 10, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kuqwjo7IgkQzz5kx2lvxUifh5PJqKD4osqL50H4STJiQbr5AJqQCKI","news_summary":"Nucleai Partners with Protean BioDiagnostics to Improve Cancer Diagnosis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e8af93d0-d40f-4637-a2ef-4ef4c00f8b71","date":"Apr 10, 2019","link":"https://medcitynews.com/2019/04/israeli-startup-leverages-ai/","source":"medcitynews.com","visible":1,"analysis":{"tags":"healthcare, AI","company":"Nucleai","layoffs":null,"summary":"Israeli startup Nucleai, founded in 2017, is using AI-based technology to assist pathologists in analyzing slides and creating accurate reports for GI, breast, and prostate biopsies. The companys tool can be utilized for quality assurance checks and as a digital resident that generates initial reports for pathologists to review. Nucleai has raised $5 million in funding and has customers in Israel, the U.S., and Europe. The company plans to expand its capabilities to more labs and organizations in the U.S. and Europe and is on the verge of signing strategic partnerships with various companies.","partners":"not mentioned","customers":"not mentioned","investors":null,"confidence":8,"key_topics":["pathologists","AI-based system","biopsies","funding","strategic partnerships"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fHXurCHR0tDXl5WkkuXo6da5tG4fqxrr5K5C73ZsyibO6xyshDEnZQ","news_summary":"This Israeli startup leverages AI to help pathologists handle their workload","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a0b348ef-d8c7-458d-83c6-08a15d722c46","date":"Mar 12, 2019","link":"https://www.prnewswire.com/news-releases/nucleai-announces-participation-in-united-states-and-canadian-academy-of-pathology-uscap-annual-meeting-2019-300810843.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"AI, pathology","company":"Nucleai","layoffs":null,"summary":"Nucleai, an AI company specializing in pathology, will be exhibiting at the 2019 United States and Canadian Academy of Pathology (USCAP) conference. The company offers AI-based analysis of biopsies to improve cancer diagnostics. Nucleais products analyze biopsies in the GI, breast, and prostate categories, providing increased efficiency and accuracy for pathologists. The company will be presenting its latest research on digital image analysis and artificial intelligence-based digital image analysis at the conference. Nucleai aims to improve the standard of care in oncology and has raised $5 million in funding to date.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["AI","pathology","cancer diagnostics","biopsies","USCAP"],"date_of_event":"March 16-21, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Jt3B8uKb7RipRIEc4fnldhVGGrzZkExQTgY1OcLqBujeTODZTiHJrV","news_summary":"Nucleai Announces Participation in United States and Canadian Academy of Pathology (USCAP) Annual Meeting 2019","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9c67de92-9e0f-4e2e-92e0-aa3703c8f552","date":"Jun 26, 2018","link":"https://globenewswire.com/news-release/2018/06/26/1529579/0/en/Precipio-and-Nucleai-Partner-to-Develop-Artificial-Intelligence-Powered-Hemepath-Solution.html","source":"globenewswire.com","visible":1,"analysis":{"tags":["artificial intelligence","pathology","diagnostics"],"company":"Precipio, Inc.","layoffs":null,"summary":"Specialty diagnostics company Precipio has announced an agreement with Nucleai, an Israel-based artificial intelligence pathology platform company. Nucleais technology uses machine learning and machine vision algorithms to assist pathologists in the detection of cancer using biopsy image analysis. The partnership will focus on adapting the platform to the identification of abnormalities in hematopoietic malignancies. The use of Nucleais technology is expected to reduce scanning time, improve accuracy, and increase the throughput of cases. The collaboration aims to provide a more accurate diagnosis and potentially save resources and lives in cancer care. Precipios expertise and partnerships with academic-level medical school pathology departments will contribute to the development of the platform. The companies estimate that the time spent by hematopathologists on the morphologic assessment can be reduced by as much as 50%, resulting in potential cost savings and improved diagnostic outcomes.","partners":["Nucleai"],"customers":null,"investors":null,"confidence":8,"key_topics":["AI pathology platform","diagnostic accuracy","hematopathology","cancer care","misdiagnosis"],"date_of_event":"2018-06-26","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QMkHd129KmesnhIUGSvScVywTFfpFCdXXta9tqNAfDW9gtDbDMLzY0","news_summary":"Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eb40dc71-ca8f-4fce-be6f-c2c315772f16","date":"Apr 1, 2018","link":"https://www.forbes.com/sites/startupnationcentral/2018/03/29/sequoia-index-andreesen-samsung-just-backed-these-israeli-startups/#4cb4b2f4541d","source":"www.forbes.com","visible":1,"analysis":{"tags":"startup funding","company":"Start-Up Nation Central","layoffs":null,"summary":"The article highlights several Israeli startups that have recently raised funding. The startups mentioned are AudioBurst, Nucleai, PixCell Medical, Capitolis, eToro, BioCatch, Luminate Security, and RapidAPI. The investments and funding rounds range from Samsung Venture Investment investing in AudioBurst to eToro raising $100M in a Round E. The article discusses startups in various sectors such as AI, digital health, fintech, cyber, and software. The funding and investments mentioned in the article indicate positive growth for the companies involved.","partners":null,"customers":null,"investors":["Samsung Venture Investment","Vertex Ventures","Grove Venture","Sequoia Capital","Index Ventures","Guy Gamzu","Spark Capital","BRM Group","Maverick Ventures","American Express Ventures","NexStar Partners","Kreos Capital","CreditEase","OurCrowd","JANVEST Capital","U.S. Venture Partners","Aleph Venture Capital","Microsofts ScaleUp program","Andreessen Horowitz"],"confidence":9,"key_topics":["AI","Digital-health","Fintech","Cyber","Software"],"date_of_event":"March 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3DfTvBzIfNnZFKjSjBunIrHT22wHAd2C5CQaThEz8yD37d6qxGc9y4","news_summary":"Sequoia, Index, Andreessen And Samsung Just Backed These Israeli Startups","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e45e16bb-8ebf-4bf4-bfc6-8eea6f00e4a3","date":"Mar 7, 2018","link":"http://tissuepathology.com/2018/03/07/israeli-ai-cancer-startup-lands-5-million/#axzz594JePZZm","source":"tissuepathology.com","visible":1,"analysis":{"tags":"AI, Healthcare, Funding","company":"Nucleai","layoffs":"Not mentioned","summary":"Israeli start-up Nucleai has raised $5m in a seed funding round led by Vertex Ventures Israel and Grove Ventures Capital. The company is developing an artificial intelligence (AI) pathology system to help pathologists detect signs of cancer and gastrointestinal diseases. The technology is designed to improve the efficiency of pathologists, reduce errors and shorten patients wait time for a diagnosis. The AI market for healthcare applications is expected to grow at 40% annually through 2021 and reach $6.7bn by that year, according to a report by Frost & Sullivan.","partners":"Not mentioned","customers":"Not mentioned","investors":["Vertex Ventures Israel","Grove Ventures Capital (GP) Ltd"],"confidence":9,"key_topics":["AI Pathology","Funding","Cancer Detection","Healthcare","Technology"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"$5 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"f2xqnM0Zh072PMvjVipnMnOMfRD8UOjtukeSxPauU8JmrM5Ucddr26","news_summary":"Israeli AI Cancer Startup Lands $5 Million  Tissuepathology.com","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9457ed52-0057-4f20-951e-3e9ac52faf33","date":"Mar 6, 2018","link":"https://www.timesofisrael.com/israeli-startup-aims-at-disease-diagnosis-helping-pathologists-process-biopsies/","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":"AI pathology","company":"Nucleai","layoffs":null,"summary":"Israeli startup Nucleai is developing an AI pathology system to help pathologists process and analyze biopsies more accurately and quickly. The company has raised $5 million in financing from Vertex Ventures, Grove Ventures, and private investors. Nucleais software uses computer vision, algorithms, and artificial intelligence to scan biopsies and identify problematic ones for pathologists. The technology will be deployed in hospitals and research centers in Israel and the US. The global AI market for healthcare applications is expected to reach $6.7 billion by 2021. Nucleai plans to double its team by recruiting experienced machine learning researchers.","partners":null,"customers":null,"investors":"Vertex Ventures, Grove Ventures, Brian Cooper, Nir Kalkstein","confidence":9,"key_topics":["AI pathology","Computer vision","Artificial intelligence","Pathologists","Biopsies"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Customers","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1316Xsfp3Pn5nweoeFcyFQJ5klDrt5K5NZ1Rulcm3fGmUB1vw8U4m0","news_summary":"Israeli startup aims at disease diagnosis, helping pathologists process biopsies","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"977aa647-268e-44fb-825c-1c66ca4c37ab","date":"Mar 5, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3733307,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"artificial intelligence, software","company":"Nucleai Ltd.","layoffs":null,"summary":"Tel Aviv-based Nucleai Ltd. has completed a $5 million Seed Round led by Vertex Ventures Israel and Grove Ventures Capital (GP) Ltd. The company develops software that uses artificial intelligence to diagnose abnormalities in tissue samples, particularly for detecting cancerous cells and gastrointestinal diseases. Nucleais technology aims to improve the efficiency of pathologists, reduce errors, and shorten patients wait time for a diagnosis. The company plans to launch a pilot in hospitals and labs in the U.S. and Israel in the coming months. Nucleai was founded in 2017 and is looking to double the size of its team.","partners":null,"customers":null,"investors":"Vertex Ventures Israel, Grove Ventures Capital (GP) Ltd.","confidence":9,"key_topics":["Nucleai","software","artificial intelligence","cancer detection","Seed Round"],"date_of_event":"05.03.18","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zSfyFvM6bBvsdQQiSNrV3TjTJazyol17H93r3jtKDih5IycbOd3Xr8","news_summary":"AI Cancer Detection Startup Nucleai Raises $5 Million","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":25,"techcommunityinvolvement":null,"mediagallery":[{"id":"RuPZFV2vQp8KzbtXR8ZIqFIQNetIQ5LHLF8Taf0AA7dRN8hBl6pVVH","timestamp":"2024-06-04 14:46:57.000000","resources_type":2,"resources_title":"","resources_file_name":"K6a2beoQs_s","alt":"","imageurl":"https://img.youtube.com/vi/K6a2beoQs_s/0.jpg","url":"http://youtu.be/K6a2beoQs_s"}],"tags":["bioconvergence","cancer-diagnostics","healthcare-providers","machine-learning","diagnostics","oncology","cancer","digital-healthcare","deep-learning","artificial-intelligence","computer-vision","precision-medicine","medical-technologies","hospitals","imaging","biomarkers","software-platform","cloud-based","laboratories","decision-support","pharmaceuticals","pharma-companies","immunotherapy","clinical-trials"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":[],"geomarkets":["Europe","United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":11,"lastfunding":"$14M","totalrounds":4,"fundingstage":"B","totalfunding":"$60.5M","publicinvestors":11,"lastpublicfunding":14000000,"totalpublicrounds":4,"totalpublicfunding":60500000},"team":[{"name":"Avi Veidman","email":"avi@nuclaimd.com","phone":"0529462672","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNSh6oYKDA","bounced":false,"claimed":1,"founder":1,"urlname":"avi-veidman-3","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg7P3y2AgM","position":"Co-founder & CEO","last_name":"Veidman","claimtoken":"fa7c0a83511dab3844e45d6a591ce398bf82a39e68a1f18497350fdeccd38dd6","first_name":"Avi","picturekey":"$h4f66NVpvJwd7CjlMPe9XfZi9bl0LMsx1DqlLKvZgkzvOWu33GkXta","claimeddate":"2018-05-13","linkedinurl":"https://www.linkedin.com/in/avi-veidman","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2018-05-13 14:34:34.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$h4f66NVpvJwd7CjlMPe9XfZi9bl0LMsx1DqlLKvZgkzvOWu33GkXta","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eliron Amir","email":"eliron@nucleaimd.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoKnm0pwJDA","bounced":false,"claimed":1,"founder":1,"urlname":"eliron-amir-2","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgqey-8goM","position":"Co-founder & COO","last_name":"Amir","claimtoken":"f4ad8126d3853a9fc8f897c60513ffb6f11556b78834ca431abbefb0410a8a48","first_name":"Eliron","picturekey":"$lQt4nqdpJwLNqbYsI2x6vapa0ZtOqPrfYF0zWfnecp2wyzP8ZGwbhY","claimeddate":"2018-05-14","linkedinurl":"https://www.linkedin.com/in/eliron-amir","unsubscribed":false,"is_activeuser":1,"additionalemail":"elirona@gmail.com","claimedemaildate":"2018-05-14 15:16:23.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$lQt4nqdpJwLNqbYsI2x6vapa0ZtOqPrfYF0zWfnecp2wyzP8ZGwbhY","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Lotan Chorev","email":"lotan@nucleaimd.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoMn93_gLDA","bounced":true,"claimed":1,"founder":1,"urlname":"lotan-chorev-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgqezg3QgM","position":"Co-founder & VP R&D","last_name":"Chorev","claimtoken":"cba41b1be32cd6c2719927b0f1d7bc05b59f25c8be10da18c101d35bb47f4b0d","first_name":"Lotan","picturekey":"$ZZc27NCWH0hIjOAuMt3pFLOrB4h8Ov7xKUkGt1rjqrCPX7OjdeCNP7","claimeddate":"2018-05-13","linkedinurl":"https://www.linkedin.com/in/lotan-chorev","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2018-05-13 17:55:43.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$ZZc27NCWH0hIjOAuMt3pFLOrB4h8Ov7xKUkGt1rjqrCPX7OjdeCNP7","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Albert Achtenberg","email":"albert@nucleaimd.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OHa7tcKDA","bounced":false,"claimed":0,"founder":0,"urlname":"albert-achtenberg","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg0aGdjAkM","position":"CTO","last_name":"Achtenberg","claimtoken":"OgxiOeqnZzaOddwfBFxbEmpvRNE3ovuruQWwRgSuDfEkCQBGFLQe75","first_name":"Albert","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/achtenberg/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2022-09-14 18:15:38.000000","initials":"AA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Neelima  Kumar","email":"neelima.kumar@nucleai.ai","phone":"","gender":"Female","userid":"CNDINMSp306wh8N1WY8fn4zgnKBRzHm6SF2KxwXAziMMC40V9F8Cp8","bounced":false,"claimed":null,"founder":0,"urlname":"neelima-kumar","visible":1,"memberid":"0jrmDL5nwpOz5exgbWVJMARYGY3ARelO4qDmUo7yQ8pQNX1M3hLVh4","position":"Head of Marketing","last_name":"Kumar","claimtoken":"qmHlcRM5MsKWBSs948F4AKv1y1os5AsiI6oXBaxH0TOIiZgQiJuq1p","first_name":"Neelima ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/neelimakumar/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-07-03 13:18:29.000000","initials":"NK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Liat Ben senior","email":"liat.bensenior@nucleai.ai","phone":"","gender":"Female","userid":"YWzd92k2Nr4zS138bl8MNPWlLMWjGAufWH3nSPxf9iuoTE7ZYpGYrW","bounced":false,"claimed":null,"founder":0,"urlname":"liat-ben","visible":1,"memberid":"Vj525YsAlPVN6AogXIINEBXLfvFIug93hnym1gXK7URWIONW8tQntE","position":"Director of Marketing ","last_name":"Ben senior","claimtoken":"3l4iAdliAHPsMqA0r3x5Q1ZMNFbyzrHRnhLkH2IPQd8id3EzUSrO4o","first_name":"Liat","picturekey":null,"claimeddate":null,"linkedinurl":null,"unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-07-31 06:38:39.000000","initials":"LB","pictureurl":"/assets/empty-state.svg","linkedin-display":"none","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoPW8rMQKDA","fullname":"Lena Rogovina"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2020-03-04T00:00:00.000Z","crunchbaseid":"nucleai","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2017-10-29T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":"Lena Rogovina","affiliatedOrganizations":null,"timeline":[{"id":"pbxf3OMpUkTg4ucm5APDJR4S0JptHVt1GzZNgttS3lTrvokxaeDVVy","date":"Apr 2024","amount":"$14M","source":"https://www.calcalistech.com/ctechnews/article/r11brac1a","eventtype":"FundingRoundEvent","investment":[{"name":"M Ventures","type":"Investor","amount":null,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/ms-ventures-israel-bioincubator","logokey":"$T9rrER6ccOAeHaUhrRclT8sLHnVVdbnxSAW33L0YVjduN9k2EI95Nh","tagline":null,"urlname":"/investor_page/ms-ventures-israel-bioincubator","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL-llZsJDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"yAEnqsjsvuYJrmgV5s0ZX7E9Fx1yYjCAUYYUVEDNfTbdvxhzoMUEH6","fundingsubtype":"Corporate VC","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$T9rrER6ccOAeHaUhrRclT8sLHnVVdbnxSAW33L0YVjduN9k2EI95Nh","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Debiopharm Innovation Fund","type":"Investor","amount":null,"hidden":false,"country":"Switzerland","fullurl":"/investor_page/debiopharm-innovation-fund","logokey":"$Q1TqCHDntGSFJCThM1fLenpHpphk8eK4UinUTMoEUSFsVIH13FuHcH","tagline":"Venture capital arm of Debiopharm Group","urlname":"/investor_page/debiopharm-innovation-fund","isisraeli":0,"investorid":"Ym4Ae5x1vRSyizA2gxqkGoYWXFk60OQc8w4sHkYEPMoIKQ6pCqjAFD","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"5CD3eyWxuLSpOsn5ihYpiycIIMb4Rj8EOTWz9cmUBRCvImk2K4rvMH","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Q1TqCHDntGSFJCThM1fLenpHpphk8eK4UinUTMoEUSFsVIH13FuHcH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Vertex Ventures Israel","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/vertex-ventures-israel","logokey":"$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","tagline":null,"urlname":"/investor_page/vertex-ventures-israel","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6_vosJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HQZiMAxUugNdbu9owU24KUfqK4fjw5PGCDYPhVfIXpQAKGkhTncCDa","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Sanofi Ventures","type":"Investor","amount":null,"hidden":false,"country":"France","fullurl":"/investor_page/sanofi-ventures","logokey":"$7EXYnik4dg1YdzXwTFiMJeMK4A1xHfEjEK2of6haOeTwKXxZWUgFXu","tagline":"","urlname":"/investor_page/sanofi-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODrmNKMCQw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"PFUloMLjjALXEMQ4FahoKnhiIAhpge9gsBjVqXF5haaZS7UuFFsptm","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7EXYnik4dg1YdzXwTFiMJeMK4A1xHfEjEK2of6haOeTwKXxZWUgFXu","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Grove Ventures","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/grove-ventures","logokey":"$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","tagline":null,"urlname":"/investor_page/grove-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLioiJYKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"jhSDsBbFf1hNDmMrIUSgIJFhF0vLNVKSVoFL9zsJ5HAelOOi1U5EFc","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Section 32","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/section-32","logokey":"$80F64q8pJc9aD7xG5G9gR19ClxF9fNF8HDqgCrIoodKCeJxrajEsEl","tagline":"","urlname":"/investor_page/section-32","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODHr_bRCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"mMVlFxZ8Ufprv21F2q7GBLOk408Dr2tJ0VoZrxBkM8LunORhIz69E5","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$80F64q8pJc9aD7xG5G9gR19ClxF9fNF8HDqgCrIoodKCeJxrajEsEl","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Fosun RZ Capital","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/fosun-rz-capital","logokey":"$SJ0VGeY3KCQstkmmnQgIAOSjCHZouL0rJdgnB97jgClcpEmgYMG2TO","tagline":null,"urlname":"/investor_page/fosun-rz-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KHMgLALDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"n5hyob3VsZ1dUsVT1IL4SLvT6eVVW6yi98qnN6nsmKeto5y993kHq7","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$SJ0VGeY3KCQstkmmnQgIAOSjCHZouL0rJdgnB97jgClcpEmgYMG2TO","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":14000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJD0tYqOCgw","date":"Mar 2022","amount":"$33M","source":"https://www.calcalist.co.il/ctechnews/article/rjiw007pg9","eventtype":"FundingRoundEvent","investment":[{"name":"Sanofi Ventures","type":"Investor","amount":0,"hidden":false,"country":"France","fullurl":"/investor_page/sanofi-ventures","logokey":"$7EXYnik4dg1YdzXwTFiMJeMK4A1xHfEjEK2of6haOeTwKXxZWUgFXu","tagline":"","urlname":"/investor_page/sanofi-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODrmNKMCQw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"16b1f152-706d-4e03-a18f-407789df0857","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7EXYnik4dg1YdzXwTFiMJeMK4A1xHfEjEK2of6haOeTwKXxZWUgFXu","leadcaption":"","followupcaption":""},{"name":"Vertex Ventures Israel","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vertex-ventures-israel","logokey":"$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","tagline":null,"urlname":"/investor_page/vertex-ventures-israel","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6_vosJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"370b5566-80bb-4597-9278-e1279f1d3f28","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","leadcaption":"","followupcaption":"Follow on "},{"name":"Fosun RZ Capital","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/fosun-rz-capital","logokey":"$SJ0VGeY3KCQstkmmnQgIAOSjCHZouL0rJdgnB97jgClcpEmgYMG2TO","tagline":null,"urlname":"/investor_page/fosun-rz-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KHMgLALDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4b5f9f27-fb72-4b72-8b10-20aac91c9562","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$SJ0VGeY3KCQstkmmnQgIAOSjCHZouL0rJdgnB97jgClcpEmgYMG2TO","leadcaption":"","followupcaption":""},{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"741738ec-6a5a-46fc-9fce-49d053ca0ea9","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Grove Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/grove-ventures","logokey":"$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","tagline":null,"urlname":"/investor_page/grove-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLioiJYKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9f730edc-1381-444f-a8ae-fc9ec681466c","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","leadcaption":"","followupcaption":"Follow on "},{"name":"Section 32","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/section-32","logokey":"$80F64q8pJc9aD7xG5G9gR19ClxF9fNF8HDqgCrIoodKCeJxrajEsEl","tagline":"","urlname":"/investor_page/section-32","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODHr_bRCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"aaa02d25-f5c6-4596-b148-ddb660d26331","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$80F64q8pJc9aD7xG5G9gR19ClxF9fNF8HDqgCrIoodKCeJxrajEsEl","leadcaption":"","followupcaption":""},{"name":"Debiopharm Group","type":"Company","amount":0,"hidden":true,"country":"Switzerland","fullurl":"/company_page/debiopharm-group","logokey":"$gWWcoedolwbEtx8c4G3Evbbvh0UeQuHJKgiMEK4NmTxRYsgS22ByNN","tagline":"Pharmaceutical Company ","urlname":"/company_page/debiopharm-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCBv-L6CQw","fundingtype":"Company","leadpartner":null,"investmentid":"f7b6560d-cd78-4ac6-8fea-e2f9a9834973","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$gWWcoedolwbEtx8c4G3Evbbvh0UeQuHJKgiMEK4NmTxRYsgS22ByNN","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":33000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJCwptuvCww","hub":"BeyondBio SCALE","date":"Oct 2021","batch":"2","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KarzuIKDA","source":"https://www.calcalist.co.il/ctechnews/article/ryxjtjjmq","enddate":"Apr 2022","hub_type":"Corporate Accelerator","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/beyondbio-scale","hub_logokey":"$GKQys2ISctzGq4yatr4EcHcNR7XHE0b24C47VOPM2pB8FpW4zM9QbS","hub_urlname":"/program_page/beyondbio-scale","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$GKQys2ISctzGq4yatr4EcHcNR7XHE0b24C47VOPM2pB8FpW4zM9QbS","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODRkpWxCAw","date":"Jul 2020","amount":"$8.5M","source":"Added by Eliron Amir","eventtype":"FundingRoundEvent","investment":[{"name":"Debiopharm Group","type":"Company","amount":0,"hidden":true,"country":"Switzerland","fullurl":"/company_page/debiopharm-group","logokey":"$gWWcoedolwbEtx8c4G3Evbbvh0UeQuHJKgiMEK4NmTxRYsgS22ByNN","tagline":"Pharmaceutical Company ","urlname":"/company_page/debiopharm-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCBv-L6CQw","fundingtype":"Company","leadpartner":null,"investmentid":"0300e607-86dc-4542-832f-dba62d28c408","fundingsubtype":"","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$gWWcoedolwbEtx8c4G3Evbbvh0UeQuHJKgiMEK4NmTxRYsgS22ByNN","leadcaption":"Lead ","followupcaption":""},{"name":"Grove Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/grove-ventures","logokey":"$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","tagline":null,"urlname":"/investor_page/grove-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLioiJYKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1ef3163b-a440-4442-b7d9-231ae1e3570f","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","leadcaption":"","followupcaption":"Follow on "},{"name":"Vertex Ventures Israel","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vertex-ventures-israel","logokey":"$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","tagline":null,"urlname":"/investor_page/vertex-ventures-israel","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6_vosJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7e3ee567-a5c8-46f9-ad06-fc8a9e02cbf1","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmsf5CAw","date":"Mar 2018","amount":"$5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Grove Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/grove-ventures","logokey":"$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","tagline":null,"urlname":"/investor_page/grove-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLioiJYKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1a188b01-4d32-4353-bf82-daa5a54cce37","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","leadcaption":"","followupcaption":""},{"name":"Nir Kalkstein","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/nir-kalkstein","logokey":"$hu1E6prePmMfOqUgU3cbBWcBdO3I5bYRzrsT5rL8itkZxxQMnCp7b8","tagline":"","urlname":"/investor_page/nir-kalkstein","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEjZPHCQw","fundingtype":"Angel","leadpartner":null,"investmentid":"37abaff1-1677-4a37-80d1-ca8e2ba8ff11","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$hu1E6prePmMfOqUgU3cbBWcBdO3I5bYRzrsT5rL8itkZxxQMnCp7b8","leadcaption":"","followupcaption":""},{"name":"Vertex Ventures Israel","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vertex-ventures-israel","logokey":"$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","tagline":null,"urlname":"/investor_page/vertex-ventures-israel","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6_vosJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5c28cdb4-0cb4-4d6d-944b-0cf3ed63f868","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","leadcaption":"","followupcaption":""},{"name":"Brian Cooper","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/brian-cooper","logokey":null,"tagline":"","urlname":"/investor_page/brian-cooper","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8afKCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"6c23443b-960d-4cf8-be62-bcb3763dfa67","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"ujccz3BM0yW6Zm7w2xO2W1UxkVAuioCD1YIGugQaWEB3du5DfkUXvr","hub":"Arc Innovation Center","date":"","batch":"","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Nzf9a0IDA","source":"","enddate":"","hub_type":"Corporate Accelerator","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/arc-innovation-center","hub_logokey":"$h4kVs9Y8FIw1PlL9peLoiBUHlwkeM0hVe5lCktvnAuF1BF3VW20V0c","hub_urlname":"/program_page/arc-innovation-center","eventvisibility":null,"amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$h4kVs9Y8FIw1PlL9peLoiBUHlwkeM0hVe5lCktvnAuF1BF3VW20V0c","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"7/2017","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Nucleai","logourl":"https://storage.googleapis.com/clean-finder-353810/$eOzUd6AY1bx7e3hU7ZOp773EdpuzthMglqf079ifRuRMsJQIhZ976L.png","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$eOzUd6AY1bx7e3hU7ZOp773EdpuzthMglqf079ifRuRMsJQIhZ976L.png","seoabout":"Nucleai’s technology leverages intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions in a patient’s biopsy, trans...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":6,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Decision Support","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Machine Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"},{"depth":1,"name":"Data Storage","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","classificationName":"coretechnology"},{"depth":2,"name":"Cloud","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Laboratories","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Machine Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA>Cloud#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Laboratories#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Medical Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA>Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Medical Decision Support#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Machine Learning#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA|1:>TechnologyClassificationModel/Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA|2:>TechnologyClassificationModel>Data Storage#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA/Cloud#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA|1:>TechnologyClassificationModel/Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA|2:>TechnologyClassificationModel>Platforms & Interfaces#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA/Software#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Laboratories#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Digital Healthcare","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Medical Decision Support","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Medical Decision Support"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Healthcare","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Providers","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"},{"title":"Laboratories","key":"0-0-1-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Laboratories"}]}]}],"coreTechnology":[{"title":"Artificial Intelligence","key":"0-0","path":"TechnologyClassificationModel>Artificial Intelligence","children":[{"title":"Machine Learning","key":"0-0-0","path":"TechnologyClassificationModel>Artificial Intelligence>Machine Learning"},{"title":"Computer Vision","key":"0-0-1","path":"TechnologyClassificationModel>Artificial Intelligence>Computer Vision"}]},{"title":"Data Storage","key":"0-1","path":"TechnologyClassificationModel>Data Storage","children":[{"title":"Cloud","key":"0-1-0","path":"TechnologyClassificationModel>Data Storage>Cloud"}]},{"title":"Platforms & Interfaces","key":"0-2","path":"TechnologyClassificationModel>Platforms & Interfaces","children":[{"title":"Software","key":"0-2-0","path":"TechnologyClassificationModel>Platforms & Interfaces>Software"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Decision Support","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety7cLDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Machine Learning","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81fgLDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"},{"depth":1,"name":"Data Storage","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQ4b8IDA","classificationName":"coretechnology"},{"depth":2,"name":"Cloud","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgJDA","classificationName":"coretechnology"},{"depth":1,"name":"Platforms & Interfaces","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NuxioUJDA","classificationName":"coretechnology"},{"depth":2,"name":"Software","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1i8MIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Laboratories","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PvpscQIDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Digital Healthcare","Medical Decision Support"],"coreTechnology":["Artificial Intelligence","Machine Learning","Computer Vision","Data Storage","Cloud","Platforms & Interfaces","Software"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Healthcare","Providers","Laboratories"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"pbxf3OMpUkTg4ucm5APDJR4S0JptHVt1GzZNgttS3lTrvokxaeDVVy","date":"Apr 2024","amount":"$14M","source":"https://www.calcalistech.com/ctechnews/article/r11brac1a","eventtype":"FundingRoundEvent","investment":[{"name":"M Ventures","type":"Investor","amount":null,"hidden":false,"country":"Netherlands","fullurl":"/investor_page/ms-ventures-israel-bioincubator","logokey":"$T9rrER6ccOAeHaUhrRclT8sLHnVVdbnxSAW33L0YVjduN9k2EI95Nh","tagline":null,"urlname":"/investor_page/ms-ventures-israel-bioincubator","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL-llZsJDA","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"yAEnqsjsvuYJrmgV5s0ZX7E9Fx1yYjCAUYYUVEDNfTbdvxhzoMUEH6","fundingsubtype":"Corporate VC","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$T9rrER6ccOAeHaUhrRclT8sLHnVVdbnxSAW33L0YVjduN9k2EI95Nh","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Debiopharm Innovation Fund","type":"Investor","amount":null,"hidden":false,"country":"Switzerland","fullurl":"/investor_page/debiopharm-innovation-fund","logokey":"$Q1TqCHDntGSFJCThM1fLenpHpphk8eK4UinUTMoEUSFsVIH13FuHcH","tagline":"Venture capital arm of Debiopharm Group","urlname":"/investor_page/debiopharm-innovation-fund","isisraeli":0,"investorid":"Ym4Ae5x1vRSyizA2gxqkGoYWXFk60OQc8w4sHkYEPMoIKQ6pCqjAFD","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"5CD3eyWxuLSpOsn5ihYpiycIIMb4Rj8EOTWz9cmUBRCvImk2K4rvMH","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Q1TqCHDntGSFJCThM1fLenpHpphk8eK4UinUTMoEUSFsVIH13FuHcH","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""},{"name":"Vertex Ventures Israel","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/vertex-ventures-israel","logokey":"$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","tagline":null,"urlname":"/investor_page/vertex-ventures-israel","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6_vosJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HQZiMAxUugNdbu9owU24KUfqK4fjw5PGCDYPhVfIXpQAKGkhTncCDa","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Sanofi Ventures","type":"Investor","amount":null,"hidden":false,"country":"France","fullurl":"/investor_page/sanofi-ventures","logokey":"$7EXYnik4dg1YdzXwTFiMJeMK4A1xHfEjEK2of6haOeTwKXxZWUgFXu","tagline":"","urlname":"/investor_page/sanofi-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODrmNKMCQw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"PFUloMLjjALXEMQ4FahoKnhiIAhpge9gsBjVqXF5haaZS7UuFFsptm","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7EXYnik4dg1YdzXwTFiMJeMK4A1xHfEjEK2of6haOeTwKXxZWUgFXu","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Grove Ventures","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/grove-ventures","logokey":"$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","tagline":null,"urlname":"/investor_page/grove-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLioiJYKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"jhSDsBbFf1hNDmMrIUSgIJFhF0vLNVKSVoFL9zsJ5HAelOOi1U5EFc","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Section 32","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/section-32","logokey":"$80F64q8pJc9aD7xG5G9gR19ClxF9fNF8HDqgCrIoodKCeJxrajEsEl","tagline":"","urlname":"/investor_page/section-32","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODHr_bRCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"mMVlFxZ8Ufprv21F2q7GBLOk408Dr2tJ0VoZrxBkM8LunORhIz69E5","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$80F64q8pJc9aD7xG5G9gR19ClxF9fNF8HDqgCrIoodKCeJxrajEsEl","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"Fosun RZ Capital","type":"Investor","amount":null,"hidden":false,"country":"China","fullurl":"/investor_page/fosun-rz-capital","logokey":"$SJ0VGeY3KCQstkmmnQgIAOSjCHZouL0rJdgnB97jgClcpEmgYMG2TO","tagline":null,"urlname":"/investor_page/fosun-rz-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KHMgLALDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"n5hyob3VsZ1dUsVT1IL4SLvT6eVVW6yi98qnN6nsmKeto5y993kHq7","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$SJ0VGeY3KCQstkmmnQgIAOSjCHZouL0rJdgnB97jgClcpEmgYMG2TO","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":14000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJD0tYqOCgw","date":"Mar 2022","amount":"$33M","source":"https://www.calcalist.co.il/ctechnews/article/rjiw007pg9","eventtype":"FundingRoundEvent","investment":[{"name":"Sanofi Ventures","type":"Investor","amount":0,"hidden":false,"country":"France","fullurl":"/investor_page/sanofi-ventures","logokey":"$7EXYnik4dg1YdzXwTFiMJeMK4A1xHfEjEK2of6haOeTwKXxZWUgFXu","tagline":"","urlname":"/investor_page/sanofi-ventures","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODrmNKMCQw","fundingtype":"Corporate VC","leadpartner":null,"investmentid":"16b1f152-706d-4e03-a18f-407789df0857","fundingsubtype":"Corporate VC","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$7EXYnik4dg1YdzXwTFiMJeMK4A1xHfEjEK2of6haOeTwKXxZWUgFXu","leadcaption":"","followupcaption":""},{"name":"Vertex Ventures Israel","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vertex-ventures-israel","logokey":"$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","tagline":null,"urlname":"/investor_page/vertex-ventures-israel","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6_vosJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"370b5566-80bb-4597-9278-e1279f1d3f28","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","leadcaption":"","followupcaption":"Follow on "},{"name":"Fosun RZ Capital","type":"Investor","amount":0,"hidden":false,"country":"China","fullurl":"/investor_page/fosun-rz-capital","logokey":"$SJ0VGeY3KCQstkmmnQgIAOSjCHZouL0rJdgnB97jgClcpEmgYMG2TO","tagline":null,"urlname":"/investor_page/fosun-rz-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KHMgLALDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4b5f9f27-fb72-4b72-8b10-20aac91c9562","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$SJ0VGeY3KCQstkmmnQgIAOSjCHZouL0rJdgnB97jgClcpEmgYMG2TO","leadcaption":"","followupcaption":""},{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"741738ec-6a5a-46fc-9fce-49d053ca0ea9","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Grove Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/grove-ventures","logokey":"$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","tagline":null,"urlname":"/investor_page/grove-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLioiJYKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"9f730edc-1381-444f-a8ae-fc9ec681466c","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","leadcaption":"","followupcaption":"Follow on "},{"name":"Section 32","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/section-32","logokey":"$80F64q8pJc9aD7xG5G9gR19ClxF9fNF8HDqgCrIoodKCeJxrajEsEl","tagline":"","urlname":"/investor_page/section-32","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODHr_bRCQw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"aaa02d25-f5c6-4596-b148-ddb660d26331","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$80F64q8pJc9aD7xG5G9gR19ClxF9fNF8HDqgCrIoodKCeJxrajEsEl","leadcaption":"","followupcaption":""},{"name":"Debiopharm Group","type":"Company","amount":0,"hidden":true,"country":"Switzerland","fullurl":"/company_page/debiopharm-group","logokey":"$gWWcoedolwbEtx8c4G3Evbbvh0UeQuHJKgiMEK4NmTxRYsgS22ByNN","tagline":"Pharmaceutical Company ","urlname":"/company_page/debiopharm-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCBv-L6CQw","fundingtype":"Company","leadpartner":null,"investmentid":"f7b6560d-cd78-4ac6-8fea-e2f9a9834973","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$gWWcoedolwbEtx8c4G3Evbbvh0UeQuHJKgiMEK4NmTxRYsgS22ByNN","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":33000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODRkpWxCAw","date":"Jul 2020","amount":"$8.5M","source":"Added by Eliron Amir","eventtype":"FundingRoundEvent","investment":[{"name":"Debiopharm Group","type":"Company","amount":0,"hidden":true,"country":"Switzerland","fullurl":"/company_page/debiopharm-group","logokey":"$gWWcoedolwbEtx8c4G3Evbbvh0UeQuHJKgiMEK4NmTxRYsgS22ByNN","tagline":"Pharmaceutical Company ","urlname":"/company_page/debiopharm-group","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCBv-L6CQw","fundingtype":"Company","leadpartner":null,"investmentid":"0300e607-86dc-4542-832f-dba62d28c408","fundingsubtype":"","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$gWWcoedolwbEtx8c4G3Evbbvh0UeQuHJKgiMEK4NmTxRYsgS22ByNN","leadcaption":"Lead ","followupcaption":""},{"name":"Grove Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/grove-ventures","logokey":"$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","tagline":null,"urlname":"/investor_page/grove-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLioiJYKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1ef3163b-a440-4442-b7d9-231ae1e3570f","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","leadcaption":"","followupcaption":"Follow on "},{"name":"Vertex Ventures Israel","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vertex-ventures-israel","logokey":"$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","tagline":null,"urlname":"/investor_page/vertex-ventures-israel","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6_vosJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"7e3ee567-a5c8-46f9-ad06-fc8a9e02cbf1","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":8500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCkmsf5CAw","date":"Mar 2018","amount":"$5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Grove Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/grove-ventures","logokey":"$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","tagline":null,"urlname":"/investor_page/grove-ventures","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwLioiJYKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1a188b01-4d32-4353-bf82-daa5a54cce37","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$n4AHC9JNL8UoAR7yguMpBlRFWXOp9AkDTErvx7uuoQcLXJ1dRsa5nb","leadcaption":"","followupcaption":""},{"name":"Nir Kalkstein","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/nir-kalkstein","logokey":"$hu1E6prePmMfOqUgU3cbBWcBdO3I5bYRzrsT5rL8itkZxxQMnCp7b8","tagline":"","urlname":"/investor_page/nir-kalkstein","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEjZPHCQw","fundingtype":"Angel","leadpartner":null,"investmentid":"37abaff1-1677-4a37-80d1-ca8e2ba8ff11","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$hu1E6prePmMfOqUgU3cbBWcBdO3I5bYRzrsT5rL8itkZxxQMnCp7b8","leadcaption":"","followupcaption":""},{"name":"Vertex Ventures Israel","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vertex-ventures-israel","logokey":"$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","tagline":null,"urlname":"/investor_page/vertex-ventures-israel","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgP6_vosJDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5c28cdb4-0cb4-4d6d-944b-0cf3ed63f868","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$fy4wfRBWYAqSVpK8faW0Jot838HvOJig6Kdfm7Hf4FgXARarmHt0vn","leadcaption":"","followupcaption":""},{"name":"Brian Cooper","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/brian-cooper","logokey":null,"tagline":"","urlname":"/investor_page/brian-cooper","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCk8afKCAw","fundingtype":"Angel","leadpartner":null,"investmentid":"6c23443b-960d-4cf8-be62-bcb3763dfa67","fundingsubtype":"Angel","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}